Recent Finacing
Recent Raise
Rigontec develops synthetic RNA RIG-I agonists to activate innate immunity for oncology, anti-infective, and inflammatory indications, advancing a preclinical pipeline and lead RGT100 toward clinical development.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors